Literature DB >> 32487817

The OATH Syndemic: opioids and other substances, aging, alcohol, tobacco, and HIV.

Julie A Womack1,2, Amy C Justice1,3.   

Abstract

PURPOSE OF REVIEW: Persons living with HIV (PLWH) are aging, continue to use alcohol and other substances, and experience age-associated adverse effects. We explore a new syndemic: OATH (opioids and other substances, aging, alcohol, tobacco, and HIV). RECENT
FINDINGS: Frailty and falls are important problems that affect the health status of PLWH who continue to use alcohol and other substances. HIV, alcohol and other substance use, and aging each contributes to inflammaging. Multimorbidity and polypharmacy are also important pathways as alcohol and other substances interact with prescribed medications resulting in adverse-drug interactions leading to potentially serious consequences. Social conditions including racism, poverty, sex bias, stress, and stigma contribute to the existence and persistence of this syndemic.
SUMMARY: Substance use, HIV, and aging are linked in a new syndemic (OATH) that drives age-related outcomes such as frailty and falls. We need to expand our understanding of the 'healthcare team' so that we include social and political advocates who can support necessary structural change. Treatment of substance use should be better incorporated into the management of HIV, including a focus on potential medication/substance interactions. Finally, we need to explore treatment of frailty rather than individual manifestations of frailty (e.g., atherosclerosis, neurodegeneration).

Entities:  

Year:  2020        PMID: 32487817      PMCID: PMC7422477          DOI: 10.1097/COH.0000000000000635

Source DB:  PubMed          Journal:  Curr Opin HIV AIDS        ISSN: 1746-630X            Impact factor:   4.283


  5 in total

1.  NIH Workshop on HIV-Associated Comorbidities, Coinfections, and Complications: Summary and Recommendation for Future Research.

Authors:  Savita Pahwa; Steven Deeks; Shimian Zou; Natalie Tomitch; Leia Miller-Novak; Elisabet Caler; Amy Justice; Ned Sacktor; Dana Gabuzda; Peter W Hunt; Todd Brown; Ann Kurth; Stefan Baral; Michael Mugavero; Kenneth H Mayer; Emily Mendenhall; Roger Detels; Vincent Mutabazi
Journal:  J Acquir Immune Defic Syndr       Date:  2021-01-01       Impact factor: 3.771

2.  Estimation of time of HIV seroconversion using a modified CD4 depletion model.

Authors:  Viviane D Lima; Lu Wang; Paul Sereda; Taylor McLinden; Rolando Barrios; Julio S G Montaner
Journal:  PLoS One       Date:  2021-02-12       Impact factor: 3.240

Review 3.  Ageing and older people who use illicit opioids, cocaine or methamphetamine: a scoping review and literature map.

Authors:  Camille Zolopa; Stine B Høj; Nanor Minoyan; Julie Bruneau; Iuliia Makarenko; Sarah Larney
Journal:  Addiction       Date:  2022-02-10       Impact factor: 7.256

4.  Multimorbidity networks associated with frailty among middle-aged and older people with HIV.

Authors:  David R Lorenz; Shibani S Mukerji; Vikas Misra; Hajime Uno; Benjamin B Gelman; David J Moore; Elyse J Singer; Susan Morgello; Dana Gabuzda
Journal:  AIDS       Date:  2021-12-01       Impact factor: 4.177

Review 5.  Consensus statement on the role of health systems in advancing the long-term well-being of people living with HIV.

Authors:  Jeffrey V Lazarus; Kelly Safreed-Harmon; Adeeba Kamarulzaman; Jane Anderson; Ricardo Baptista Leite; Georg Behrens; Linda-Gail Bekker; Sanjay Bhagani; Darren Brown; Graham Brown; Susan Buchbinder; Carlos Caceres; Pedro E Cahn; Patrizia Carrieri; Georgina Caswell; Graham S Cooke; Antonella d'Arminio Monforte; Nikos Dedes; Julia Del Amo; Richard Elliott; Wafaa M El-Sadr; María José Fuster-Ruiz de Apodaca; Giovanni Guaraldi; Tim Hallett; Richard Harding; Margaret Hellard; Shabbar Jaffar; Meaghan Kall; Marina Klein; Sharon R Lewin; Ken Mayer; Jose A Pérez-Molina; Doreen Moraa; Denise Naniche; Denis Nash; Teymur Noori; Anton Pozniak; Reena Rajasuriar; Peter Reiss; Nesrine Rizk; Jürgen Rockstroh; Diana Romero; Caroline Sabin; David Serwadda; Laura Waters
Journal:  Nat Commun       Date:  2021-07-16       Impact factor: 14.919

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.